Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  American Journal of Cardiology

• Publication date

  2013-04-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.amjcard.2012.12.037PMID 23352266
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Statins and risk of treated incident diabetes in a primary care population.

  2013cited by this paper
• The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

  2012cited by this paper
• Caveats to aggressive lowering of lipids by specific statins.

  2012cited by this paper
• Statins and the risk of new-onset diabetes: a review of recent evidence

  2011cited by this paper
• Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation.

  2011cited by this paper
• NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials

  2011cited by this paper
• Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.

  2011cited by this paper
• Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.

  2010cited by this paper
• Abstract 15351: Significant Differential Metabolic Effects of Rosuvastatin and Pravastatin in Hypercholesterolemic Patients

  2010cited by this paper
• The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration

  2009cited by this paper
• Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

  2008cited by this paper
• Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.

  2008cited by this paper
• Rosuvastatin in older patients with systolic heart failure.

  2007cited by this paper
• Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial.

  2006cited by this paper
• High-dose atorvastatin after stroke or transient ischemic attack.

  2006cited by this paper
• High-dose atorvastatin after stroke or transient ischemic attack.

  2006cited by this paper
• Intensive lipid lowering with atorvastatin in patients with stable coronary disease.

  2005cited by this paper
• High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.

  2005cited by this paper
• National cross sectional survey to determine whether the decision to delivery interval is critical in emergency caesarean section

  2004cited by this paper
• Combination of direct and indirect evidence in mixed treatment comparisons

  2004cited by this paper
• Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial.

  2003cited by this paper
• MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.

  2003cited by this paper
• Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

  2002cited by this paper
• Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.

  2002cited by this paper
• Pravastatin and the Development of Diabetes Mellitus: Evidence for a Protective Treatment Effect in the West of Scotland Coronary Prevention Study

  2001cited by this paper
• Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

  1998cited by this paper
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

  1994cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• Comparative study of obeticholic acid and rosuvastatin in high-fat/fructose diet–induced metabolic dysfunction: role of AMPK, PPAR-γ, SREBP-1c, and STAT3 pathways

  2026cites this paper
• Impact of statin therapy on glycemic status in diabetes-naïve patients: a systematic review

  2026cites this paper
• Managing hypertension, diabetes, and dyslipidemia in frail older adults

  2025cites this paper
• Longitudinal Association of Statin Treatment With Insulin Sensitivity and Beta-Cell Function in the PROMISE Cohort

  2025cites this paper
• Duration and type of statin use and long-term risk of type 2 diabetes among men and women with hypercholesterolaemia: findings from three prospective cohorts

  2025cites this paper
• Challenges in the clinical care of major cardiovascular conditions in primary care: a narrative review.

  2025cites this paper
• Low LDL-C: Is It all Good News?

  2024cites this paper
• Statine: Nebenwirkungen – alternative Therapieoptionen

  2024cites this paper
• Effect of rosuvastatin versus atorvastatin on new-onset diabetes mellitus in patients treated with high-intensity statin therapy for coronary artery disease: a post-hoc analysis from the LODESTAR randomized clinical trial

  2024influential citation
• High-dose atorvastatin therapy progressively decreases skeletal muscle mitochondrial respiratory capacity in humans

  2024cites this paper
• Case report: dyslipidaemia—dramatic increase in haemoglobin A1c following statin initiation

  2024cites this paper
• Cholesterol Lowering in Older Adults: Should We Wait for Further Evidence?

  2024cites this paper
• The Impact of Cardiovascular Drugs in Hyperglycemia and Diabetes: A review of 'Unspoken Side' Effect.

  2024cites this paper
• Advances in the molecular mechanisms of statins in regulating endothelial nitric oxide bioavailability: Interlocking biology between eNOS activity and L-arginine metabolism.

  2024cites this paper
• Comparative efficacy, toxicity, and insulin-suppressive effects of simvastatin and pravastatin in fatty acid-challenged mouse insulinoma MIN6 β-cell model

  2024cites this paper
• Medication-Induced Hyperglycemia and Diabetes Mellitus: A Review of Current Literature and Practical Management Strategies

  2024cites this paper
• Debate: Lipid-lowering Therapies and Diabetes Development

  2024cites this paper
• Statin Use and Hyperglycemia: Do Statins Cause Diabetes?

  2024cites this paper
• Androgenic condition and statins: contradictions in modern literature

  2024cites this paper
• Diabetes and cardiovascular disease in older adults

  2024cites this paper
• Association between blood lipids and diabetes mellitus in older Chinese adults aged 65 years or older: a cross-sectional analysis of residents’ electronic health records

  2024cites this paper
• Potential Benefits and Risks Associated with the Use of Statins

  2024cites this paper
• Exploring the Association of Lipid-Lowering Drugs with Diabetes: A Comprehensive Review

  2024cites this paper
• The Diagnosis and Treatment of Lipid Abnormalities in Pediatric Patients

  2024cites this paper
• Statin use and incident type 2 diabetes mellitus in women after menopause.

  2024cites this paper
• Combination Lipid-Lowering Therapy in Patients Undergoing Percutaneous Coronary Intervention.

  2023cites this paper
• Do Statins Counteract the Effect of Antidiabetic Drugs? Results of the SCEAD Study

  2023cites this paper
• Risk of diabetes with statins

  2023cites this paper
• The Benefits Outweigh the Risks of Treating Hypercholesterolemia: The Statin Dilemma

  2023cites this paper
• The Effect of Statins on Male Reproductive Parameters: A Mechanism Involving Dysregulation of Gonadal Hormone Receptors and TRPV1

  2023cites this paper
• Autophagy–urea cycle pathway is essential for the statin-mediated nitric oxide bioavailability in endothelial cells

  2023cites this paper
• Management of dyslipidemia in older adults

  2023cites this paper
• Modifiable statin characteristics associated with potential statin‐related prescribing cascades

  2023influential citation
• Cholesterol Paradox in Older People with Type 2 Diabetes Mellitus Regardless of Lipid-Lowering Drug Use: A Cross-Sectional Cohort Study

  2023cites this paper
• Medical Management of Dyslipidemia for Secondary Stroke Prevention: Narrative Review

  2023cites this paper
• A novel machine learning-based screening identifies statins as inhibitors of the calcium pump SERCA

  2023cites this paper
• Drug-induced hyperglycemia and diabetes.

  2023cites this paper
• The effects of simvastatin and fenofibrate on malondialdehyde and reduced glutathione concentrations in the plasma, liver, and brain of normolipidaemic and hyperlipidaemic rats

  2023cites this paper
• Statins may increase diabetes, but benefit still outweighs risk

  2023cites this paper
• Statins and new-onset diabetes in primary prevention setting: an updated meta-analysis stratified by baseline diabetes risk

  2023cites this paper
• Effects of statin therapy on glycemic control and insulin resistance: A systematic review and meta-analysis.

  2023cites this paper
• Hidroksi Metil Glutaril Coenzyme-A (HMG CoA) Reduktase Inhibitor and New Onset Diabetes Mellitus: A Review of Correlation and Clinical Implication

  2023cites this paper
• Assessing the Incidence of New-onset Diabetes Mellitus with Statin Use: A Systematic Review of the Systematic Reviews and Meta-analyses

  2022cites this paper
• The Impact of Age on Statin-Related Glycemia: A Propensity Score-Matched Cohort Study in Korea

  2022cites this paper
• Statins and Male Fertility: Is There a Cause for Concern?

  2022cites this paper
• Comparative effects of rosuvastatin and atorvastatin on the risk of new-onset diabetes mellitus in patients with acute coronary syndrome receiving percutaneous coronary intervention: a retrospective cohort study

  2022cites this paper
• Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association

  2022cites this paper
• 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee.

  2022cites this paper
• Building reliable evidence from real-world data: methods, cautiousness and recommendations

  2022cites this paper
• X chromosome dosage drives statin-induced dysglycemia and mitochondrial dysfunction

  2022cites this paper
• Common and Rare PCSK9 Variants Associated with Low-Density Lipoprotein Cholesterol Levels and the Risk of Diabetes Mellitus: A Mendelian Randomization Study

  2022cites this paper
• Safety of ezetimibe in lipid-lowering treatment: systematic review and meta-analysis of randomised controlled trials and cohort studies

  2022cites this paper
• Safety of proprotein convertase subtilisin/kexin 9 inhibitors: a systematic review and meta-analysis

  2022cites this paper
• Impact of pitavastatin on new-onset diabetes mellitus compared to atorvastatin and rosuvastatin: a distributed network analysis of 10 real-world databases

  2022cites this paper
• Evaluation of glycemic status among hypercholesterolemic patients on atorvastatin in a tertiary care hospital – A retrospective study

  2022cites this paper
• Polypharmacy in Hospice and Palliative Care.

  2022cites this paper
• Side effects of statins-from pathophysiology and epidemiology to diagnostic and therapeutic implications.

  2022cites this paper
• Statin-Induced Geranylgeranyl Pyrophosphate Depletion Promotes PCSK9–Dependent Adipose Insulin Resistance

  2022cites this paper
• A Paradigm Shift in Dyslipidemia Management in Primary Care: A 12-Month Cohort Study.

  2022cites this paper
• Using Mendelian randomisation to identify opportunities for type 2 diabetes prevention by repurposing medications used for lipid management

  2022cites this paper
• Undertreatment or Overtreatment With Statins: Where Are We?

  2022cites this paper
• Management of Dyslipidemia after Stroke

  2022cites this paper
• The Challenge: Finding the Most Appropriate Statin and Dose for Each Patient.

  2021cites this paper
• A Mendelian Randomization Approach Using 3-HMG-Coenzyme-A Reductase Gene Variation to Evaluate the Association of Statin-Induced Low-Density Lipoprotein Cholesterol Lowering With Noncardiovascular Disease Phenotypes

  2021cites this paper
• Statins: The Backbone of Treatment of Dyslipidemia

  2021cites this paper
• Impact of PCSK9 Immunization on Glycemic Indices in Diabetic Rats

  2021cites this paper
• EFFECT OF STATINS ON THE PERIODONTAL LIGAMENT OF INDUCED DIABETIC RATS

  2021cites this paper
• Drugs Interfering with Insulin Resistance and Their Influence on the Associated Hypermetabolic State in Severe Burns: A Narrative Review

  2021cites this paper
• Is the effect of atorvastatin 60 mg on stabilization of lipid‐rich plaque equivalent to that of rosuvastatin 10 mg? A serial optical coherence tomography combined with intravascular ultrasound imaging

  2021cites this paper
• Improvement of Platelet Respiration by Cell–Permeable Succinate in Diabetic Patients Treated with Statins

  2021cites this paper
• STATINS: ADVERSE RESPONSES, OXIDATIVE STRESS AND METABOLIC COMMUNICATIONS – A NARRATIVE REVIEW

  2020cites this paper
• Statins and diabetes: focus on pitavastatin

  2020cites this paper
• Statin use increased new-onset diabetes in hypercholesterolemic individuals: Data from the Korean National Health Insurance Service-National Health Screening Cohort database (NHIS-HEALS).

  2020cites this paper
• Statin Intolerance Clinical Guide 2018

  2020cites this paper
• Rationale for the use of metformin and exercise to counteract statin‐associated side effects

  2020cites this paper
• Simvastatin profoundly impairs energy metabolism in primary human muscle cells

  2020cites this paper
• Statin therapy for primary prevention in the elderly and its association with new-onset diabetes, cardiovascular events and all-cause mortality.

  2020cites this paper
• Differential Diabetogenic Effect of Pitavastatin and Rosuvastatin, in vitro and in vivo

  2020cites this paper
• The association of statins for secondary prevention with progression to diabetes in patients with prediabetic state after coronary artery bypass graft surgery: A retrospective cohort study.

  2020cites this paper
• Statins and Higher Diabetes Mellitus Risk: Incidence, Proposed Mechanisms, and Clinical Implications

  2020cites this paper
• Statin Use is Associated With Insulin Resistance in Participants of the Canadian Multicentre Osteoporosis Study

  2020cites this paper
• Time-varying and dose-dependent effect of long-term statin use on risk of type 2 diabetes: a retrospective cohort study

  2020cites this paper
• ЕВРАЗИЙСКИЕ КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ ПО ДИАГНОСТИКЕ И ЛЕЧЕНИЮ ОСТРОГО КОРОНАРНОГО СИНДРОМА С ПОДЪЕМОМ СЕГМЕНТА ST (ОКСПST)

  2020cites this paper
• Current perspectives on the use of statins in the treatment of dyslipidaemic patients: focus on pitavastatin

  2020cites this paper
• Abrogation of postprandial triglyceridemia with dual PPAR α/γ agonist in type 2 diabetes mellitus: a randomized, placebo-controlled study

  2020cites this paper
• LDL-C plays a causal role on T2DM: a Mendelian randomization analysis

  2020cites this paper
• Statin Treatment-Induced Development of Type 2 Diabetes: From Clinical Evidence to Mechanistic Insights

  2020cites this paper
• Medicinal plants and bioactive natural compounds as inhibitors of HMG‐CoA reductase: A literature review

  2020cites this paper
• The use of Statins in the elderly is associated with less severe hypoglycemia in patient with diabetes.

  2020cites this paper
• Lipid-Lowering Therapy and Low-Density Lipoprotein Cholesterol (LDL-C) Goal Achievement in High-Cardiovascular-Risk Patients in Fuzhou, China

  2020cites this paper
• Medication-induced hyperglycemia: pediatric perspective

  2020cites this paper
• EURASIAN CLINICAL GUIDELINES ON DIAGNOSIS AND TREATMENT OF ACUTE CORONARY SYNDROME WITH ST SEGMENT ELEVATION (STEMI)

  2020cites this paper
• The role of the ERK1:STAT1 serine 727 phosphorylation axis on key atherosclerosis associated cellular processes and the anti-atherogenic actions of hydroxytyrosol

  2019cites this paper
• Statin treatment and increased diabetes risk. Possible mechanisms.

  2019cites this paper
• Statins an oft-prescribed drug is implicated in peripheral neuropathy: The time to know more.

  2019cites this paper
• Statin therapy: does sex matter?

  2019cites this paper
• Associations of statin use with glycaemic traits and incident type 2 diabetes

  2019cites this paper
• 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

  2019cites this paper
• Low density lipoprotein mimics insulin action on autophagy and glucose uptake in endothelial cells

  2019cites this paper
• [The problem of safety of lipid-lowering therapy].

  2019cites this paper